9. Bots M.L., Baldassarre D., Simon A. et al. Carotid intima-media thickness and coronary atherosclerosis: weak or strong relations? Eur Heart J. 2007 Feb;28(4):398–406. doi: 10.1093/eurheartj/ehl482. www.ncbi.nlm.nih.gov/pubmed/17277033 (дата обращения: 04.02.2021).
10. Taylor A.J., Bindeman J., Le T.P. et al. Progression of calcified coronary atherosclerosis: relationship to coronary risk factors and carotid intima-media thickness. Atherosclerosis. 2008 Mar;197(1):339-45. doi: 10.1016/j.atherosclerosis.2007.05.027. www.ncbi.nlm.nih.gov/pubmed/17727858 (дата обращения: 04.02.2021).
11. Gronewold J., Bauer M., Lehmann N. et al. Coronary artery calcification, intimamedia thickness, and ankle-brachial index are complementary stroke predictors. Stroke.
2014 Sep;45(9):2702-9. doi: 10.1161/STROKEAHA.114.005626. www.ncbi.nlm.nih. gov/pubmed/25116876 (дата обращения: 04.02.2021).
12. Amato M., Montorsi P., Ravani A. et al. Carotid intima-media thickness by B-mode ultrasound as surrogate of coronary atherosclerosis: correlation with quantitative coronary angiography and coronary intravascular ultrasound findings. Eur Heart J. 2007 Sep;28(17):2094-101. doi: 10.1093/eurheartj/ehm244. www.ncbi.nlm.nih.gov/ pubmed/17597051 (дата обращения: 04.02.2021).
13. Lorenz M.W., Bickel H., Bots M.L. et al. Individual progression of carotid intima media thickness as a surrogate for vascular risk (PROG-IMT): Rationale and design of a metaanalysis project. Am Heart J. 2010 May;159(5):730–736.e2. doi: 10.1016/j.ahj.2010.02.008. www.ncbi.nlm.nih.gov/pubmed/20435179 (дата обращения: 04.02.2021).
14. Den Ruijter H.M., Peters S.A., Anderson T.J. et al. Common carotid intimamedia thickness measurements in cardiovascular risk prediction: a meta-analysis. JAMA. 2012 Aug 22;308(8):796–803. doi: 10.1001/jama.2012.9630. www.ncbi.nlm.nih.gov/ pubmed/22910757 (дата обращения: 04.02.2021).
15. Hughes B.G., Hekimi S. Different Mechanisms of Longevity in Long-Lived Mouse and Caenorhabditis elegans Mutants Revealed by Statistical Analysis of Mortality Rates. Genetics. 2016 Nov;204(3):905–920. doi: 10.1534/genetics.116.192369. www.ncbi. nlm.nih.gov/pubmed/27638422 (дата обращения: 04.02.2021).
16. Biemel K.M., Friedl D.A., Lederer M.O. Identification and quantification of major maillard cross-links in human serum albumin and lens protein. Evidence for glucosepane as the dominant compound. J Biol Chem. 2002 Jul 12;277(28):24907-15. doi: 10.1074/jbc. M202681200. www.ncbi.nlm.nih.gov/pubmed/11978796 (дата обращения: 04.02.2021).
17. Narayan K.M., Boyle J.P., Thompson T.J. et al. Lifetime risk for diabetes mellitus in the United States. JAMA. 2003 Oct 8;290(14):1884-90. doi: 10.1001/jama.290.14.1884. www.ncbi.nlm.nih.gov/pubmed/14532317 (дата обращения: 04.02.2021).
18. Bannister C.A., Holden S.E., Jenkins-Jones S. et al. Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls. Diabetes Obes Metab. 2014 Nov;16(11):1165-73. doi: 10.1111/dom.12354. www.ncbi. nlm.nih.gov/pubmed/25041462 (дата обращения: 04.02.2021).
19. Gavrilov L.A., Gavrilova N.S. The quest for a general theory of aging and longevity. Sci Aging Knowledge Environ. 2003 Jul 16;2003(28):RE5. doi: 10.1126/sageke.2003.28. re5. www.ncbi.nlm.nih.gov/pubmed/12867663 (дата обращения: 04.02.2021).
20. Mancia G., De Backer G., Dominiczak A. et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2007 Jun;28(12):1462-536. doi: 10.1093/eurheartj/ehm236. www. ncbi.nlm.nih.gov/pubmed/17562668 (дата обращения: 04.02.2021).
21. 7.1.1. Дисфункция эндотелия. Приложение 3 к журналу «Кардиоваскулярная терапия и профилактика», 2009; 8(6). Файловый архив студентов. (Электронный ресурс) URL: https://studfile.net/preview/4381218/page:4 (дата обращения: 04.02.2021).
22. Fedintsev A., Kashtanova D., Tkacheva O. et al. Markers of arterial health could serve as accurate non-invasive predictors of human biological and chronological age. Aging (Albany NY). 2017 Apr;9(4):1280–1292. doi: 10.18632/aging.101227. www.ncbi. nlm.nih.gov/pubmed/28455973 (дата обращения: 04.02.2021).
23. Zhang Y., Koradia A., Kamato D. et al. Treatment of atherosclerotic plaque: perspectives on theranostics. J Pharm Pharmacol. 2019 Jul;71(7):1029–1043. doi: 10.1111/jphp.13092. www.ncbi.nlm.nih.gov/pubmed/31025381 (дата обращения: 04.02.2021).
24. Meng L., Jin W., Wang X. RIP3-mediated necrotic cell death accelerates systematic inflammation and mortality. Proc Natl Acad Sci U S A. 2015 Sep 1;112(35):11007-12. doi: 10.1073/pnas.1514730112. www.ncbi.nlm.nih.gov/pubmed/26283397 (дата обращения: 04.02.2021).
25. Ridker P.M., Danielson E., Fonseca F.A. et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008 Nov 20;359(21):2195-207. doi: 10.1056/NEJMoa0807646. www.ncbi.nlm.nih.gov/ pubmed/18997196 (дата обращения: 04.02.2021).
26. Ma Q., Zhou Y., Zhai G. et al. Meta-Analysis Comparing Rosuvastatin and Atorvastatin in Reducing Concentration of C-Reactive Protein in Patients With Hyperlipidemia. Angiology. 2016 Jul;67(6):526-35. doi: 10.1177/0003319715599863. www.ncbi.nlm.nih.gov/pubmed/26271127 (дата обращения: 04.02.2021).
27. Xie N., Chen M., Dai R. et al. SRSF1 promotes vascular smooth muscle cell proliferation through a A133p53/EGR1/KLF5 pathway. Nat Commun. 201 7 Aug 11;8:16016. doi: 10.1038/ncomms16016. www.ncbi.nlm.nih.gov/pubmed/28799539 (дата обращения: 04.02.2021).
28. Wells J.M., Gaggar A., Blalock J.E. MMP generated matrikines. Matrix Biol. May-Jul 2015;44–46:122-9. doi: 10.1016/j.matbio.2015.01.016. www.ncbi.nlm.nih.gov/ pubmed/25636538 (дата обращения: 04.02.2021).
29. Плотина. [Фото] (Электронный ресурс) URL: https://www.shutterstock.ru.
30. Stansell A. Roster of St. Francis Dam Victims. October 2011 – February 2014. Update 1-17-2018. (Электронный ресурс) URL: https://scvhistory.com/scvhistory/ annstansell_damvictims022214.htm (дата обращения: 04.02.2021).
31. Porter K.E., Naik J., Turner N.A. et al. Simvastatin inhibits human saphenous vein neointima formation via inhibition of smooth muscle cell proliferation and migration. J Vasc Surg. 2002 Jul;36(1):150-7. doi: 10.1067/mva.2002.122029. www.ncbi.nlm.nih. gov/pubmed/12096273 (дата обращения: 04.02.2021).
32. Pozzi A., Yurchenco P.D., lozzo R.V. The nature and biology of basement membranes. Matrix Biol. 2017 Jan;57–58:1-11. doi: 10.1016/j.matbio.2016.12.009. www.ncbi.nlm.nih.gov/pubmed/28040522 (дата обращения: 04.02.2021).
33. Gan J., Li P., Wang Z., et al. Rosuvastatin suppresses platelet-derived growth factor-BB-induced vascular smooth muscle cell proliferation and migration via the MAPK signaling pathway. Exp Ther Med. 2013 Oct;6(4):899–903. doi: 10.3892/etm.2013.1265. www.ncbi.nlm.nih.gov/pubmed/24137286 (дата обращения: 04.02.2021).
34. Benigni A., Corna D., Zoja C. et al. Disruption of the Ang II type 1 receptor promotes longevity in mice. J Clin Invest. 2009 Mar;119(3):524-30. doi: 10.1172/ JCI36703. www.ncbi.nlm.nih.gov/pubmed/19197138 (дата обращения: 04.02.2021).
35. Telmisartan. (Электронный ресурс) URL: www.drugs.com/monograph/ telmisartan.html (дата обращения: 04.02.2021).
36. Brun B.F., Strela F.B., Berger R.C.M. et al. Blockade of AT1 receptor restore the migration of vascular smooth muscle cells in high sodium medium. Cell Biol Int. 2019 Aug;43(8):890–898. doi: 10.1002/cbin.11162. www.ncbi.nlm.nih.gov/pubmed/31062893 (дата обращения: 04.02.2021).
37. Patrushev. N., Seidel-Rogol B., Salazar G. Angiotensin II requires zinc and downregulation of the zinc transporters ZnT3 and ZnT10 to induce senescence of vascular smooth muscle cells. PLoS One. 2012;7(3):e33211. doi: 10.1371/journal.pone.0033211. www.ncbi.nlm.nih.gov/pubmed/22427991 (дата обращения: 04.02.2021).
38. Linz W., Heitsch H., Sch lkens B.A., Wiemer G. Long-term angiotensin II type 1 receptor blockade with fonsartan doubles lifespan of hypertensive rats. Hypertension. 2000 Apr;35(4):908-13. doi: 10.1161/01.hyp.35.4.908. www.ncbi.nlm.nih.gov/ pubmed/10775560 (дата обращения: 04.02.2021).
39. Linz W., Jessen T., Becker R.H. et al. Long-term ACE inhibition doubles lifespan of hypertensive rats. Circulation. 1997 Nov 4;96(9):3164-72. doi: 10.1161/01. cir.96.9.3164. www.ncbi.nlm.nih.gov/pubmed/9386189 (дата обращения: 04.02.2021).
40. Nagura J., Yamamoto M., Hui C. et al. Protective effects of ME3221 on hypertensive complications and lifespan in salt-loaded stroke-prone spontaneously hypertensive rats. Clin Exp Pharmacol Physiol. 1996 Mar;23(3):229-35. doi: 10.1111/j.1440–1681.1996. tb02601.x. www.ncbi.nlm.nih.gov/pubmed/8934613 (дата обращения: 04.02.2021).
41. Basso N., Cini R., Pietrelli A. et al. Protective effect of long-term angiotensin II inhibition. Am J Physiol Heart Circ Physiol. 2007 Sep;293(3):H1351-8. doi: 10.1152/ajpheart.00393.2007. www.ncbi.nlm.nih.gov/pubmed/17557916 (дата обращения: 04.02.2021).
42. Недогода С.В. Сартаны второго поколения: расширение терапевтических возможностей. Рациональная фармакотерапия в кардиологии. 2011;7(4)4: 477–482. (Электронный ресурс) URL: www.rpcardio.com/jour/article/viewFile/865/898 (дата обращения: 04.02.2021).
43. Eissler R.S. About the historical truth in a case of delusion. Psychoanal Rev. 1946 Oct;33(4):442-59. www.ncbi.nlm.nih.gov/pubmed/20277906 (дата обращения: 04.02.2021).
44. Caglayan E., Trappiel M., Behringer A. et al. Pulmonary arterial remodelling by deficiency of peroxisome proliferator-activated receptor-y in murine vascular smooth muscle cells occurs independently of obesity-related pulmonary hypertension. Respir Res. 2019 Feb 27;20(1):42. doi: 10.1186/s12931-019-1003-4. www.ncbi.nlm.nih.gov/ pubmed/30813929 (дата обращения: 04.02.2021).